VM
AKTX

VHCP Management’s Akari Therapeutics AKTX Stock Holding History

VHCP Management’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.11M Hold
198
– – 1.2% 17
2016
Q3 		$1.35M Hold
198
– – 1.33% 18
2016
Q2 		$2.14M Hold
198
– – 2.21% 11
2016
Q1 		$2.22M Hold
198
– – 1.92% 10
2015
Q4 		$2.3M Sell
198
-462
-70% -$6.86M 1.39% 11
2015
Q3 		$12.7M Buy
+660
New +$7.81M 3.25% 10

Other funds holding AKTX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

VHCP Management's AKTX Position: Q4 2016 in Review

VHCP Management held its Akari Therapeutics (AKTX) position steady in Q4 2016 at 198 shares worth $1.11M. The position accounts for 1.2% of the portfolio, ranked #17.

VHCP Management first reported a position in AKTX in Q3 2015 and has held it in 6 quarters since. The position peaked at $12.7M in Q3 2015. 15 funds tracked by Wall St. Rank hold AKTX as of Q4 2016.

  • VHCP Management held 198 shares of Akari Therapeutics worth $1.11M as of Q4 2016.
  • VHCP Management left its Akari Therapeutics share count unchanged in Q4 2016.
  • Akari Therapeutics made up 1.2% of VHCP Management's portfolio in Q4 2016, its #17 holding.
  • VHCP Management first reported a position in Akari Therapeutics in Q3 2015 and has held it in 6 quarters since.
  • VHCP Management's Akari Therapeutics position peaked at $12.7M in Q3 2015.
  • 15 funds tracked by Wall St. Rank held Akari Therapeutics as of Q4 2016.

Based on VHCP Management's 13F filing for Q4 2016, filed 13 Feb 2017.